DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107.

Interestingly, while non-responders as a group did not reach statistical significance in the enrichment of CD8 + T-cell signatures, we did note increases in enrichment scores for four out of five of these patients (Supplementary Fig. 15 ).

also in 111,027 other papers